Aging and the impact of global DNA methylation, telomere shortening, and total oxidative status on sarcopenia and frailty syndrome

Table 2 Global DNA methylation (% of methylated DNA) in analyzed groups

	Mean (SD)	Median (IRQ)	Min–max	N
Sarcopenia	1.1 (0.39)	1.02 (0.72)	0.61–1.65	10
Frailty syndrome	0.88 (0.32)	0.82 (0.41)	0.22–1.68	25
Geriatric control	0.79 (0.41)	0.69 (0.45)	0.20–1.77	23
HC 25–30	0.64 (0.39)	0.66 (0.38)	-0.03–1.59	24
HC 50 +	0.37 (0.29)	0.37 (0.33)	-0.23–1.08	19

HC 25–30 Healthy control subjects at 25–30 years old, HC 50 + Healthy control subjects above 50 years old, SD Standard deviation, IRQ Interquartile range, N Number of analyzed subjects in the group

ISSN: 1742-4933